IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post‐prophylaxis and late period
- 5 June 2019
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 21 (4) , e13124
Abstract
Background: Cytomegalovirus (CMV) disease represents a serious complication in liver transplant (OLT) recipients. CMV prophylaxis reduces incidence of CMV disease in the early post‐transplant period (on‐prophylaxis disease, OPD) but may postpone its manifestation after the completion of prophylaxis. Post‐prophylaxis disease (PPD) incidence after prophylaxis cessation may be modified by genetic factors.Methods: We analyzed impact of IL28B rs1297986 variants on CMV disease incidence in 743 adult OLT recipients receiving universal prophylaxis.Results: One hundred and forty‐four (19.4%) patients had at least one CMV disease episode. One hundred and two of them (70.8%) had at least one OPD and 36 (25%) patients had PPD, six (4.2%) patients had both. The rate of IL28B T allele carriers was lower in PPD group (38.9%) in comparison with OPD group (66.7%, P = 0.005) and group without CMV disease (61.4%, P = 0.009). The impact of IL28B genotype on the risk of CMV OPD was significant neither in the allelic (TT + CT vs CC, P = 0.32) nor in the recessive model (TT vs CT + CC, P = 0.79). Contrarily, in the PPD group, T allele (TT + CT vs CC) had a protective effect, OR 0.4 (95% CI 0.2‐0.8, P = 0.008). Further risk factors of PPD were age IL28B rs12979860 T allele carriers had a lower risk of CMV PPD.Keywords
This publication has 51 references indexed in Scilit:
- Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipientsLiver Transplantation, 2012
- Homozygosity for the Toll-Like Receptor 2 R753Q Single-Nucleotide Polymorphism Is a Risk Factor for Cytomegalovirus Disease After Liver TransplantationThe Journal of Infectious Diseases, 2012
- Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortGenome Medicine, 2011
- Human Cytomegalovirus IE1 Protein Elicits a Type II Interferon-Like Host Cell Response That Depends on Activated STAT1 but Not Interferon-γPLOS Pathogens, 2011
- IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCCJournal of Hepatology, 2011
- Current concepts on cytomegalovirus infection after liver transplantationWorld Journal of Hepatology, 2010
- Physical Requirements and Functional Consequences of Complex Formation between the Cytomegalovirus IE1 Protein and Human STAT2Journal of Virology, 2009
- Multifaceted Evasion of the Interferon Response by CytomegalovirusJournal of Interferon & Cytokine Research, 2009
- Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipientsTransplant International, 2005
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999